About amicus therapeutics inc. - FOLD
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
FOLD At a Glance
Amicus Therapeutics, Inc.
47 Hulfish Street
Princeton, New Jersey 08542
| Phone | 1-609-662-2000 | Revenue | 634.21M | |
| Industry | Pharmaceuticals: Major | Net Income | -27,110,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 20.048% | |
| Fiscal Year-end | 12 / 2026 | Employees | 511 | |
| View SEC Filings |
FOLD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.924 |
| Price to Book Ratio | 16.141 |
| Price to Cash Flow Ratio | 132.48 |
| Enterprise Value to EBITDA | 108.22 |
| Enterprise Value to Sales | 7.158 |
| Total Debt to Enterprise Value | 0.097 |
FOLD Efficiency
| Revenue/Employee | 1,241,115.46 |
| Income Per Employee | -53,052.838 |
| Receivables Turnover | 5.50 |
| Total Asset Turnover | 0.731 |
FOLD Liquidity
| Current Ratio | 2.843 |
| Quick Ratio | 1.881 |
| Cash Ratio | 1.234 |
FOLD Profitability
| Gross Margin | 87.325 |
| Operating Margin | 5.438 |
| Pretax Margin | 0.03 |
| Net Margin | -4.275 |
| Return on Assets | -3.125 |
| Return on Equity | -11.578 |
| Return on Total Capital | -3.783 |
| Return on Invested Capital | -4.055 |
FOLD Capital Structure
| Total Debt to Total Equity | 161.304 |
| Total Debt to Total Capital | 61.73 |
| Total Debt to Total Assets | 46.571 |
| Long-Term Debt to Equity | 158.117 |
| Long-Term Debt to Total Capital | 60.511 |